Home > Cardiology > ESC 2021 > Therapeutic heparin dosage benefits COVID-19 in-hospital patients 

Therapeutic heparin dosage benefits COVID-19 in-hospital patients 

Presented By
Prof. Alex Spyropoulos, Northwell Health, NY, USA
Conference
ESC 2021
Trial
HEP-COVID
Thromboprophylaxis with a therapeutic dose of heparin signifcantly reduced the risk of major thromboembolic events in hospitalised COVID-19 patients compared with standard therapy in the HEP-COVID trial. This benefit was only observed in those not requiring treatment in the ICU [1]. The HEP-COVID trial (NCT04401293) was designed to investigate the optimal regimen for thromboprophylaxis in high-risk, hospitalised patients with COVID-19. The study included 253 adult patients hospitalised with a COVID-19, requiring oxygen supplementation, who had either D-dimer of 4x the upper normal limit or a sepsis-induced coagulopathy (SIC) score of ≥4. They were randomised to 2 subgroups of ICU and non-ICU treatment and further to subcutaneous enoxaparin 1mg/kg twice daily or standard of care /intermediate-dose heparin (SOC group) over 10+4 days or until discharge. Prior to disch...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on